WithSecure Oyj
WithSecure Corporation: SHARE REPURCHASE 10.4.2025
WithSecure Corporation: SHARE REPURCHASE 10.4.2025
WithSecure Corporation, STOCK EXCHANGE RELEASE, 10 April 2025 at 6.30 PM (EET) | ||
WithSecure Corporation: SHARE REPURCHASE 10.4.2025 | ||
In the Helsinki Stock Exchange | ||
Trade date | 10.4.2025 | |
Bourse trade | Buy | |
Share | WITH | |
Amount | 15 000 | Shares |
Average price/ share | 0,8596 | EUR |
Total cost | 12 894,00 | EUR |
WithSecure Corporation now holds a total of 416 890 shares | ||
including the shares repurchased on 10.4.2025 | ||
The share buybacks are executed in compliance with Regulation | ||
No. 596/2014 of the European Parliament and Council (MAR) Article 5 | ||
and the Commission Delegated Regulation (EU) 2016/1052. | ||
On behalf of Withsecure Corporation | ||
Nordea Bank Oyj | ||
Janne Sarvikivi | Sami Huttunen | |
Contact information: | ||
Laura Viita | ||
Vice President Controlling, Investor relations and Sustainability | ||
WithSecure Corporation | ||
Tel. +358 50 4871044 | ||
Investor-relations@withsecure.com | ||
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
EVS Broadcast Equipment18.4.2025 18:30:00 CEST | Press release
EVS Broadcast Equipment reports update of share buyback program
AMG Critical Materials N.V.18.4.2025 18:00:00 CEST | Press release
AMG Signs Exclusive Agreement with Grupo Lagoa
Syensqo SA18.4.2025 17:45:00 CEST | Press release
Syensqo - Acquisition of own shares
Ageas18.4.2025 17:40:00 CEST | Press release
Ageas announces the Ordinary and Extraordinary General Meetings of Shareholders of ageas SA/NV
Sanofi Winthrop Industrie18.4.2025 17:15:00 CEST | Press release
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom